This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Adam Feuerstein

Senior Columnist

Before joining TheStreet in March 2001, Feuerstein covered business software for Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

Feuerstein graduated from Emory University with a bachelor's degree in political science.

Adam Feuerstein
By This Author:
Page 2 of 564

Vertex Pharma Cystic Fibrosis Combo Therapy Hits Key Endpoints in Two Pivotal Trials

By Adam Feuerstein

Based on positive study results, Vertex will seek approval for the cystic fibrosis regimen of VX-809 and Kalydeco in the fourth quarter.

07:25AM 06/24/14

Hospital Doubles Down on Northwest Bio's Cancer Vax Disclosure Criticism

By Adam Feuerstein

MD Anderson released a statement criticizing Northwest Bio on Friday night after company shareholders and supporters flamed the hospital's Facebook page with hateful comments.

09:05AM 06/23/14

Northwest Bio Fails to Refute MD Anderson Rebuke

By Adam Feuerstein

Conspicuously absent from Northwest Biotherapeutics' press release Friday was any mention of the MD Anderson Cancer Center.

09:41AM 06/20/14

Biotech Stock Mailbag: Zafgen, Bluebird, MannKind

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

08:03AM 06/20/14

Prestigious Cancer Hospital Rebukes Northwest Bio for 'Inappropriate' Data Disclosures

By Adam Feuerstein

Northwest Bio has issued five press releases and held a conference call in the past month to disclose preliminary and unconfirmed results from individual cancer patients who have had single, inoperable tumors injected repeatedly with DCVax-Direct. But investigators at MD Anderson and the two other hospitals conducting the DCVax-Direct study have not reviewed or analyzed data at all because patients are still being enrolled and treated.

08:46AM 06/19/14

A Chronological History of MannKind's Missed Partnership Promises

By Adam Feuerstein

Let's wind back the tape more than 9 years to documents the many instances in which MannKind executives made promises about partnering the inhaled insulin Afrezza.

02:25PM 06/17/14

Bluebird Bio Higher on Strong Gene Therapy Study Results

By Adam Feuerstein

Two patients with a serious, inherited blood disorder have been able to stop blood transfusions following a single treatment with an experimental gene therapy developed by Bluebird Bio, according to new but preliminary data presented Saturday.

07:28AM 06/16/14

Analyst Goes to Sweden, Returns Home Predicting Vertex CF Drug Failure

By Adam Feuerstein

Bernstein analyst Geoff Porges hung out with doctors and cystic fibrosis experts at the just-concluded European Cystic Fibrosis Society conference in Sweden and returned home even more bearish on Vertex Pharmaceuticals. In a research note Monday, Porges lays out reasons why the super-important combination studies of Kalydeco and VX-809 -- TRAFFIC and TRANPORT -- are more likely to fail.

07:01AM 06/16/14

Blood Disorder Patients Respond Strongly to Bluebird Bio Gene Therapy

By Adam Feuerstein

Two patients with a serious, inherited blood disorder have been able to stop blood transfusions following a single treatment with an experimental gene therapy developed by Bluebird Bio BLUE, according to new but preliminary data presented Saturday.

10:16AM 06/14/14

Galena Promoting Experimental Breast Cancer Drug With Faux News Articles Again

By Adam Feuerstein

Galena is paying a marketing firm to create promotions for its experimental breast cancer vaccine Neuvax. These Neuvax ads are dressed up to like legitimate news articles, except for the small disclaimer labeling them as "sponsored content paid for by a third party..."

10:11AM 06/13/14

Page 2 of 564

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,943.81 +28.74 0.17%
S&P 500 1,967.57 +2.89 0.15%
NASDAQ 4,415.49 +19.2860 0.44%

Brokerage Partners

Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs